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Purpose: To test for association between single nucleotide polymorphisms at the TGFb1 locus and the risk
of late normal tissue injury following whole breast radiotherapy.
Methods: A retrospective study compared the number of variant alleles at  509 and codons 10 and 25 of
the TGFb1 locus in women followed up in two prospective clinical trials who developed either marked
radiotherapy adverse effects or no adverse effects after matching on fractionation schedule, breast size,
surgical deﬁcit, chemotherapy and length of follow up.
Results: Median follow up in the two trials was 7.4 (maximum 15) years and 5.3 (maximum 5.3) years.
1237/1716 (72%) women with photographic assessments of radiotherapy adverse effects were alive and
well, and 147/1237 (12%) potential cases with the most marked change in photographic change in breast
appearance were matched to potential controls recording no change. In an unmatched analysis of 82
cases and 108 controls, no signiﬁcant difference in the number of genetic variants was observed.
Conclusions: No association was detected between sequence variations at the TGFb1 locus and the risk of
late adverse effects of breast radiotherapy.
 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 97 (2010) 15–18
Background
The available evidence strongly suggests that inter-patient var-
iation in normal tissue response to radiotherapy is predominantly
deterministic rather than to the random nature of radiation cell
killing [9,16]. As extrinsic factors, such as radiotherapy dosimetry,
become better controlled, factors intrinsic to the patient emerge as
potentially more important in determining tissue tolerance [17].
This recognition has spurred investigation of genetic factors asso-
ciated with late adverse effects of radiotherapy, and several high
quality reviews describe the current state of research [1,3,14].A
large number of exploratory studies and a small number of conﬁr-
matory studies have claimed associations between the probability
of developing late adverse effects of radiotherapy and the presence
of speciﬁc SNP and mutations. Positive associations have been re-
cently reviewed in APEX, ATM, CYP2D6, DNA ligase IV, eNOS,
ERCC2, ERCC4, GSTP1, SOD2, TGFB1, XPD, XRCC1, XRCC3 and
XRCC5 genes [1–2]. However, there is considerable residual uncer-
tainty for a number of reasons, including variation in the clinical
phenotype reported, difﬁculty in controlling for extrinsic factors,
the small size of most studies and publication bias. The largest
number of reports address polymorphisms at the TGFb1 locus,
although not all have been positive [6]. The current investigation
of three alleles at the TGFb1 locus was based on two randomised
trials evaluating radiotherapy in 1716 women with early breast
cancer, in whom the development of late adverse effects was pro-
spectively recorded for a minimum of 5 years [11,18].
Patients and methods
Patients
A total of 1716 patients randomised into the Royal Marsden
Hospital/Gloucestershire Oncology Centre (RMH/GOC) Breast Frac-
tionation trial (1986–1998) or the RMH Breast Radiotherapy
Dosimetry trial (1997–2000) were alive and well at the time of pa-
tient selection for the current study. The breast fractionation trial
randomised 1410 patients after complete local excision of early
breast cancer between a standard radiotherapy regimen (50 Gy
in 25 fractions) and two dose levels of a test schedule delivering
39.0 Gy and 42.9 Gy, respectively, in 13 fractions over 5 weeks
[18]. Eligibility criteria included: early stage breast cancer, invasive
carcinoma, breast-preserving surgery and patient consent. Post-
surgical photographs of both breasts were taken under standard
conditions before radiotherapy, annually to 5 years, and change
in breast appearance from baseline scored on a three-point scale.
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Annual physician assessments of breast induration were scored on
four-point graded scales. The RMH Breast Radiotherapy Dosimetry
trial randomised 306 patients between 2D versus 3D radiation
dosimetry following breast-preserving surgery for early breast
cancer [11]. Eligibility included: early breast cancer, invasive carci-
noma, breast-preserving surgery, higher than average risk of radi-
ation normal tissue changes (typically, large breast size) and
written informed consent. Radiotherapy delivered 50 Gy in 25 frac-
tions to the whole breast followed by an electron boost of 10 Gy in
ﬁve fractions. Post-surgical photographs and clinical assessments
were performed as in the fractionation trial.
Endpoint evaluation, case-control selection and sample collection
In each trial, three independent observers graded change in
breast appearance in post-treatment photographs, using the
post-surgical appearance as a comparator. Intra-observer variation
and inter-observer variation conﬁrmed the reproducibility of this
approach based on a simple graded scale (no change, mild change,
marked change). The risk of scoring any change (any change vs. no
change) in breast appearance by 5 years on serial photographs
after randomisation to 13 fractions or 3.0 or 3.3 Gy was 30.3%
and 45.7%, respectively, conﬁrming the sensitivity of this endpoint
to small dose differences [18]. Annual clinical assessments of pal-
pable induration also conﬁrmed a dose response, with moderate
or marked induration by 5 years reported after 13 fractions of 3.0
or 3.3 Gy in 16% and 35.6% of women, respectively. 1237/1716
(72%) women with photographic assessments of change in breast
appearance were alive and well at a median follow up of 7.4 (max-
imum 15) years and 5.3 (maximum 5.3) years in the two trials, of
whom 424 (35%) subjects scored some degree of change in breast
appearance. The present study planned the identiﬁcation and
recruitment of cases with the most marked changes in
photographic appearance and controls with no evidence of radia-
tion-induced change in breast appearance matched for non-genetic
co-variants, including fractionation schedule, breast size, surgical
deﬁcit, chemotherapy and length of follow up. DNA was isolated
from 20 ml whole blood collected from each research volunteer.
DNA sequencing
Polymorphisms in the vicinity of the TGFb1 locus ( 509 C/T,
codon 10 Leu/Pro & codon 25 Arg/Pro), previously reported as
showing an association with late adverse effects, were analysed
by uni-directional sequencing of the SNP region. We used primers
CACATGGGAGGTGCTCAGTA and CAGGCGGAGAAGGCTTAAT to
generate a PCR amplicon encompassing the  509 C/T variant. We
used primers CCACACCAGCCCTGTTC and CTGTTGTACAGGGCGAG-
CAC to generate a PCR amplicon that encompassed both the codon
10 leu/pro variant and the codon 25 arg/pro variant. We used a 60–
58 Touchdown protocol for both PCRs. Amplicons were then se-
quenced using the BigDyeTerminator Cycle Sequencing Kit and
an ABI 3730 automated sequencer (Applied Biosystems). Sequence
traces were analysed using Mutation Surveyor software v3.20
(SoftGenetics) and by visual inspection.
Analysis and statistical considerations
Restraining genotypic risks to only account for 30% of the severe
radiation phenotype, an analysis of 100 cases (with normal tissue
damage) and 200 matched controls (without damage) was esti-
mated to provide 80% power (a = 0.05) to demonstrate a three-fold
increase in risk associated with an allele, assuming a carrier fre-
quency >0.06. Matched analysis was not undertaken because the
number of matched pairs available for analysis was reduced due
to the failure in many instances to obtain samples from both the
case and her two assigned controls.
Ethics committee approval
Local approval was obtained from the Research Ethics Commit-
tees at the Royal Marsden NHS Foundation Trust and the Glouces-
tershire Hospitals NHS Trust.
Results
One hundred and forty-seven patients were identiﬁed with the
most marked radiotherapy phenotype based on the degree of
change in breast appearance, representing approximately 12%
(147/1237) of the total sample. As a comparator, 378 controls
matched on randomised RT regimen, boost, breast size, chemother-
apy, tamoxifen and axillary surgery were identiﬁed from 813 wo-
men recording no change in breast appearance, representing
approximately 30% of the total. Demographic data and treatment
characteristics are shown in Table 1. The planned matched analysis
was not possible, since not all cases had matched controls by the
time of the sequencing deadline. Unmatched analysis was carried
Table 1
Demographic and treatment details of cases and controls from breast dosimetry trial (BDT) and breast fractionation trial (BFT) submitted for genetic analysis.
BDT BFT
Cases Controls Cases Controls
Dose
50 Gy 31 32 20 26
42.9 Gy 0 0 21 32
39 Gy 0 0 10 18
Breast size
Small 2 3 3 5
Medium 26 27 34 58
Large 3 2 15 13
Median age years (interquartile range) 55 (50–62) 55 (50–60) 55 (47–61) 55 (46–60)
Total patients 31 32 51 76
63 127
Yes No Yes No Yes No Yes No
Chemotherapy 11 20 10 22 18 33 24 52
Axillary surgery 28 3 27 5 37 14 54 22
Axillary RT 1 30 16 16 7 44 10 66
Tamoxifen
aa aa 43 8 66 10
a Data not collected at baseline.
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out on 82 cases and 108 controls, excluding samples that had been
included in an earlier study of SNP [4]. The distribution of SNP
around candidate TGFb1 loci failed to conﬁrm an association with
late adverse effects of radiotherapy, see Table 2.
Discussion
No evidence of association between three previously examined
polymorphic TGFb1 alleles and clinical phenotype was detected.
Several reasons for missing an effect of SNP at the TGFb1 locus
can be considered, including the clinical endpoint of radiotherapy
effect, the matching of case-control pairs and statistical power.
Where the clinical endpoint is concerned, change in breast appear-
ance has been shown to be sensitive to radiotherapy dose intensity.
In 1487 patients randomised to 13 fractions of 3.0 versus 3.2 Gy
whole breast radiotherapy in the UK START-A trial, the hazard ratio
for the photographic endpoint after 3.0 Gy compared to 3.2 Gy
fractions was 0.65 (95% CI 0.49–0.85), a difference equivalent to
less than 4 Gy in 2.0 Gy fractions [8]. Telangiectasia was excluded
from the overall score, since it was typically seen in areas vulner-
able to moist desquamation, especially inframammary fold, where
it signiﬁes loss of dose sparing. The sensitivity of the photographic
endpoint to dose is a strength, but scores of breast shrinkage and
distortion correlate to underlying atrophy and ﬁbrosis, respec-
tively, each of which may have distinct genetic determinants. No
subgroup analysis was undertaken to attribute the relative contri-
butions of breast shrinkage and distortion to clinical phenotype.
The selection of cases and controls took account of patient and
treatment related factors that were systematically and prospec-
tively recorded in trial registration, treatment and follow up pro-
formas. These included breast size and surgical deﬁcit scored
from the surgical photographs (scored on three-point graded
scales), whole breast radiotherapy dose, tumour bed boost dose,
adjuvant endocrine therapy, adjuvant cytotoxic therapy and dura-
tion of follow up. Factors that were not prospectively recorded, and
could not be taken into account, included histories of acute skin
reaction, hypertension, diabetes, smoking, alcohol intake, non-can-
cer medication and collagen vascular disease. It is difﬁcult to esti-
mate the signiﬁcance of these factors for the late outcome of breast
radiotherapy, but several are risk factors for radiotherapy at other
anatomical sites [9]. In breast skin, age, menopausal status, smok-
ing habits, hypothyroidism, diabetes, hypertension, blood pressure,
cardiovascular and autoimmune disease appear to have no
inﬂuence on telangiectasia risk [17]. Overall, it seems unlikely that
inability to control for these factors undermined the study, since
genotypic risks were restrained in our sample size calculation to
account for only 30% of the radiation phenotype.
Previous reports have suggested an association between variant
TGFb1 alleles and risk of late adverse effects after radiotherapy
[4–5,10,15]. Our negative study is consistent with a recent investi-
gation of 120 patients from the Aarhus post-mastectomy trial. The
Aarhus cohort was scored for subcutaneous ﬁbrosis after hypofrac-
tionated radiotherapy without chemotherapy, including patients
who had not been previously analysed and for whom DNA could
be extracted from parafﬁn tumour blocks [6]. Based on success in
identifying breast cancer predisposition genes, there were reasons
to believe at the time our study was conceived that a limited num-
ber of high penetrance alleles might contribute to late radiation ef-
fects and be detectable with a case-control design of 100–200
patients [12]. A polygenic model of late radiation effects is now
considered likely, involving 100s or 1000s of low penetrance alleles
impacting on gene regulation rather than structural alterations in
proteins, as postulated for diabetes, hypertension and other com-
plex traits [2,13]. Collaborative studies based on well-characterised
patients entered into national and international radiotherapy trials
are needed for this. Assay technologies and costs are now able to
support such studies, opening the way for analysis of DNA banked
as part of ESTRO-GENEPI initiatives [7].
Conﬂict of interest
We declare no conﬂict of interest.
Acknowledgements
We wish to acknowledge the contributions of Prof. Nazneen
Rahman, Miss Sarah Hines and Dr. Clare Turnbull, Section of Cancer
Genetics, Institute of Cancer Research, Sutton, who were responsi-
ble for the DNA sequencing. The research was funded by Cancer
Research UK, and we acknowledge NHS funding to the NIHR Bio-
medical Research Centre.
References
[1] Alsner J, Andreassen CN, Overgaard J. Genetic markers for prediction of normal
tissue toxicity after radiotherapy. Semin Radiat Oncol 2008;18:126–35.
[2] Andreassen CN, Alsner J. Genetic variants and normal tissue toxicity after
radiotherapy: a systematic review. Radiother Oncol 2009;92:299–309.
[3] Andreassen CN, Alsner J, Overgaard J. Does variability in normal tissue
reactions after radiotherapy have a genetic basis – where and how to look
for it? Radiother Oncol 2002;64:131–40.
[4] Andreassen CN, Alsner J, Overgaard J, et al. TGFB1 polymorphisms are
associated with risk of late normal tissue complications in the breast after
radiotherapy for early breast cancer. Radiother Oncol 2005;75:18–21.
[5] Andreassen CN, Alsner J, Overgaard M, Overgaard J. Prediction of normal tissue
radiosensitivity from polymorphisms in candidate genes. Radiother Oncol
2003;69:127–35.
[6] Andreassen CN, Alsner J, Overgaard M, Sorensen FB, Overgaard J. Risk of
radiation-induced subcutaneous ﬁbrosis in relation to single nucleotide
polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATMndash; a
study based on DNA from formalin ﬁxed parafﬁn embedded tissue samples. Int
J Radiat Biol 2006;82:577–86.
[7] Baumann M, Holscher T, Begg AC. Towards genetic prediction of radiation
responses: ESTRO’s GENEPI project. Radiother Oncol 2003;69:121–5.
Table 2
Distribution in clinical cases and controls of variant alleles at candidate loci in the TGFb1 locus previously associated with late radiotherapy adverse effects.
#SNP rs# Role Amino acid change Number cases/control Genotype Cases Controls Dominant Odds Ratio (95%CI) p value
rs1800469
aPromoter, 30 UTR –, –
b81/104 C/C (WT) 44 50 0.78 (0.44–1.39) p = 0.46
C/T (het) 29 44
T/T (hom) 8 10
rs1800470 Coding exon L/P 82/108 P/P (WT) 14 19 1.04 (0.49–2.22) p = 1.00
P/L (het) 36 40
L/L (hom) 32 49
rs1800471 Coding exon R/P 82/108 R/R (WT) 66 91 1.3 (0.61–1.40) p = 0.56
R/P (het) 16 13
P/P (hom) 0 4
a UTR = untranslated region.
b DNA sequencing failed in 1 case and 4 controls.
S. Martin et al./Radiotherapy and Oncology 97 (2010) 15–18 17Author's personal copy
[8] Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast
Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment
of early breast cancer: a randomised trial. Lancet Oncol 2008;9:331–41.
[9] Bentzen SM, Overgaard J. Patient-to-patient variability in the expression of
radiation-induced normal tissue injury. Semin Radiat Oncol 1994;4:68–80.
[10] De Ruyck K, Van Eijkeren M, Claes K, et al. TGFbeta1 polymorphisms and late
clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat
Oncol Biol Phys 2006;65:1240–8.
[11] Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D
radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients
prescribed breast radiotherapy. Radiother Oncol 2007.
[12] Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A
systematic review of genetic polymorphisms and breast cancer risk. Cancer
Epidemiol Biomarkers Prev 1999;8:843–54.
[13] Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its
contribution to complex traits. Nat Rev Genet 2009;10:241–51.
[14] Popanda O, Marquardt JU, Chang-Claude J, Schmezer P. Genetic variation in
normal tissue toxicity induced by ionizing radiation. Mutat Res 2008.
[15] Quarmby S, Fakhoury H, Levine E, et al. Association of transforming growth
factor beta-1 single nucleotide polymorphisms with radiation-induced
damage to normal tissues in breast cancer patients. Int J Radiat Biol
2003;79:137–43.
[16] Safwat A, Bentzen SM, Turesson I, Hendry JH. Deterministic rather than
stochastic factors explain most of the variation in the expression of skin
telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys
2002;52:198–204.
[17] Turesson I, Nyman J, Holmberg E, Oden A. Prognostic factors for acute and late
skin reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys
1996;36:1065–75.
[18] Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of
late adverse effects in the breast after radiotherapy for early breast cancer:
long-term results of a randomised trial. Radiother Oncol 2005;75:9–17.
18 Genetic factors and normal tissue radiosensitivity